ASCI recognizes Cook with Young Physician-Scientist Award (Thursday, January 15, 2026)
The American Society for Clinical Investigation honored Daniel Cook, MD, PhD, with a Young Physician-Scientist Award, recognizing notable research achievements early in his faculty career. He was nominated by University of Iowa physician-scientist Michael Welsh, MD, and was recognized at the AAP/ASCI/APSA Joint Meeting in Chicago in April 2026.

New work shows CFTR acts as a brake on allergic T cells (2025)
Published in JCI Insight, this study from the lab and collaborators showed that the CF protein CFTR directly restrains Th2 cell development, and that the CFTR potentiator ivacaftor reduces allergic airway inflammation — suggesting CFTR modulators could be repurposed to treat type 2 inflammatory disease.

Type 2 inflammation linked to mortality in cystic fibrosis (2024)
A clinical study in Allergy, with Dr. Cook as first author, found that type 2 inflammation in people with CF predicts mortality and can be targeted with CFTR modulator therapy  — a finding that helped shape the lab's bench-to-bedside research program.